Hospital General Universitario Gregorio Marañón, Madrid, Spain;
Marianela Bringas Sr., Javier Soto Sr., Natalia Gutiérrez Alonso , Andrés J. Muñoz Martín Sr., Aitana Calvo Ferrándiz , Gabriela Torres Pérez-Solero , Laura Ortega , Rocío Martín Lozano , Roberto Jiménez Rodríguez , Irene Gonzalez Caraballo , Ana Gutierrez Ortiz de la Tabla , Carlos López Jiménez , David Salomon Juliao Caamaño , María Palma Gómez , Mónica Benavente de Lucas , Marc Ariant Cañete Muñoz , Manuel Alva Bianchi Sr., Íñigo Martínez Delfrade , Miguel Martin , Pilar Garcia-Alfonso
Background: Peritoneal metastases in patients with mCRC are commonly associated with poor outcomes. Some of these patients are candidates to undergo metastases surgery, which may result in better prognosis; however, clinical and molecular characteristics of these patients remain uncertain. Methods: We conducted a retrospective analysis of 166 patients with mCRC and peritoneal metastases in a tumor registry from 2015 to 2021, analyzing the clinical and molecular characteristics, as well as progression-free survival (PFS) and overall survival (OS) of patients who received peritoneal surgery versus those who did not. Results: From the whole population, 65 patients (39%) underwent peritoneal metastases surgery, and several characteristics were more frequent in this subgroup: ECOG 0 (n = 26, OR 2.75, p = 0,0069), age <65 years (n = 43, OR 2.29, p = 0,0162), absence of hepatic metastases (n = 56, OR 3.31, p = 0,0037), single metastatic location (n = 43, OR 3.48, p = 0,0002), normal CEA levels at diagnosis (n = 33, OR 2.02, p = 0,0455) and BRAF mutation (n = 12, OR 3.32, p = 0,0345). Moreover, these patients received more lines of systemic treatment (2.8 vs 2, p = 0,006) and more metastases surgeries (1.7 vs 0.9, p = 0,000). Significant differences in tumor mutational status regardless of BRAF (KRAS, NRAS, MSI, PI3K and HER2), sex and primary tumor location between groups were not found. PFS was longer in patients receiving metastases surgery (median, 13.68 vs 7.76 months; HR for progression 0.64; 95 % confidence interval (CI) 0.46 to 0.89; p = 0,009), as well as overall survival (median NR vs 29.53; HR for death 0.39; 95 % CI, 0.25 to 0.60; p = 0,000). Conclusions: In our cohort, patients with mCRC and peritoneal carcinomatosis who underwent metastases surgery had more frequently less than 65 years, ECOG 0, absence of liver metastases, single metastatic location, normal CEA levels at diagnosis and BRAF mutation. Moreover, this subgroup showed better outcomes with a statistically significant increase in PFS and OS.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Javier Soto Alsar
2022 ASCO Gastrointestinal Cancers Symposium
First Author: Blanca Morón García
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Takeshi Yamada
2023 ASCO Gastrointestinal Cancers Symposium
First Author: Tin-Yun Tang